• Before submitting an abstract, the submitter must create a User Profile.
• After an abstract has been created, modifications can be made until the submission deadline.
• There is no limit on the number of abstract submissions from any one individual. However, we will apply a rule of two for abstract presenter.

All abstracts should be formatted into the following four sections:

• Introduction: clarifies the motivation for the research presented.
• Methods: provides sufficient detail for others to reproduce what is studied in the research project.
• Results: presents and discusses the results.
• Conclusion: presents the outcome of the work by interpreting the findings and by relating these findings to the motivation stated in the Introduction. Explain the significance of your findings / outcomes and future implications of the results.

All abstracts must be submitted electronically through the Congress abstract submission website.

• There is no fee for submitting an abstract.
• There are no limitations on the number of abstracts that an individual can submit. However, one individual can only present two abstracts as oral presentations during the entire Congress. If you have more than 2 abstracts accepted, you will be obliged to identify alternate presenters for any abstract above the first two. The same applies for poster presentations.
• The abstract text body is limited to 3,000 characters (Approx. 400 words) including spaces. A maximum of two figures/images (in JPG, GIF, or PNG with ideally 600 dpi) can be included. These will not count toward the word limit, nor will the information about authors, institutions and study groups. File size of 2 MB maximum for each figure.
• Tables: do not insert tables into the body of the abstracts, the system will not recognize the format of the table. Tables will need to be uploaded as image files into the body of the abstract.
• Employees of Commercial Interests: AXA recognizes that employees/spouses of commercial interests are often involved in research and discovery and encourages these employees to submit abstracts to facilitate the flow of new information. Employees of commercial interests should submit abstracts when the content is limited to basic science research (e.g., pre-clinical research, drug discovery) or the processes/methodologies of research, themselves unrelated to a specific disease or compound/drug, and the abstract is not related to clinical applications of the research/discovery or clinical recommendations concerning the business lines or products of their employer.
• Ensure that all co-authors approve of the abstract submission, publication, and potential presentation. Abstracts cannot be changed or withdrawn after November 15, 2025. Once an abstract has been scored by reviewers, no change in the body of the abstract will be accepted.

Abstracts should not include libelous or defamatory content. Material presented in abstracts should not violate any copyright laws. If figures/graphics/images have been taken from sources not copyrighted by the author, it is the author’s sole responsibility to secure the rights from the copyright holder in writing to reproduce those figures/graphics/images for both worldwide print and web publication. All reproduction costs charged by the copyright holder must be borne by the author.

Abstracts that have also been submitted to IXA 2025, WTC 2025, TTS 2024 or other congresses in the past year are welcome.

AXA regards plagiarism as serious professional misconduct. All abstracts are screened for plagiarism and when identified, the abstract and any other abstracts submitted by the same author are rejected. In addition, the submitting author’s profile and scholarship application, in the case one has been submitted, will also be cancelled.

To be eligible to submit an abstract, you must disclose that the author(s)/ scientist(s) have not violated any aspect of the following Ethics Statement:

• The Declaration of Istanbul (DOI) ethics' statement
• Research conforms with the ethical statement on human research subject, Helsinki Declaration of The World Medical Association
• The Ethics of Xenotransplantation (Xenotransplantation 10:194-203, 2003) For research involving human subjects -The Helsinki.
• The Transplantation Society (TTS) Ethics statement

The AXA 2025 Xenotransplantation committee may enquire further information on the ethical aspects when evaluating the abstracts.

• All submitted abstracts will go through a blinded peer-review process carried out by at least three international referees, selected by the organizing committee.
• Abstracts which do not meet the focus of the topic category as requested by the authors will be reassigned to another category.
• Scores assigned by all reviewers are averaged. The cut-off average score for acceptance is based on available oral and poster presentations. Rejections are further evaluated by the scientific program committee.
• Poster and oral presentations are viewed as equally important components of the AXA 2025 Congress.

• Notification of acceptance or rejection will be sent to the submitting (corresponding) author by November 23, 2025. Please note that only the corresponding author will receive the communication concerning the abstract and is responsible for informing all co-authors of the status of the abstract. Authors whose abstracts have been accepted will receive instructions for the presentation of their abstract.

• Each presenting author may present a maximum of two abstracts during the entire Congress (oral or posters). The number of submissions is however not limited. Should an author have more than two abstracts accepted for presentation, a co-author must be named as presenter for one or more abstracts.